| 49318-9 |
Alpha-1-Fetoprotein interpretation |
Imp |
Amnio fld |
Pt |
Nar |
|
|
ACTIVE |
Alpha-1-Fetoprotein interpretation in Amniotic fluid Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49318-9 |
|
|
|
|
Observation |
|
|
|
0 |
AFP Interp Amn-Imp |
|
|
|
N |
|
A1; AF; AFAFP; AFP; AFP Interp; Alfa; Alpha fetoprotein; Alphafetoprotein; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; Chemistry; Feto; Gyn; Gynecology; i; Impression; Impression/interpretation of study; Impressions; Interp; Interpret; Interpretation; Interpt; Intrp; Narrative; OB; ObGyn; Obstetrics; Point in time; Random; Report; Tumor marker |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49319-7 |
Beta glucosidase activator |
Imp |
Fibroblasts |
Pt |
Nar |
|
|
ACTIVE |
Beta glucosidase activator [Interpretation] in Fibroblast Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49319-7 |
|
|
|
|
Observation |
|
|
|
0 |
B-Glucosidase Act Fib-Imp |
|
|
|
N |
|
B; B-Glucosidase Act; Chemistry; Fib; Fibr; Glucoinvertase; Glucosidosucrase; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Maltase; Maltase-glucoamylase; Narrative; Point in time; Random; Report; Saposin c |
2.21 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 4932-0 |
HLA-DQ1 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-DQ1 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4932-0 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-DQ1 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49320-5 |
Beta-N-acetylhexosaminidase.A activator |
Imp |
Fibroblasts |
Pt |
Nar |
|
|
ACTIVE |
Beta-N-acetylhexosaminidase.A activator [Interpretation] in Fibroblast Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49320-5 |
|
|
|
|
Observation |
|
|
|
0 |
Hexosaminidase A Act Fib-Imp |
|
|
|
N |
|
B; Beta-hexosaminidase subunit alpha; B-NAH; Chemistry; Fib; Fibr; GM2 activator; GM2 Gangliosidoses; GM2-gangliosidosis; Hex A; Hex B; HEXA; Hexaminidase activator; Hexosaminidase; Hexosaminidase A; Hexosaminidase A Act; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Narrative; Point in time; Random; Report; Sandhoff disease; Tay Sachs Disease |
2.21 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49321-3 |
Cerebroside sulfatase activator |
Imp |
Fibroblasts |
Pt |
Nar |
|
|
ACTIVE |
Cerebroside sulfatase activator [Interpretation] in Fibroblast Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49321-3 |
|
|
|
|
Observation |
|
|
|
0 |
Cerebro Sulfatase Act Fib-Imp |
|
|
|
N |
|
Aryl sulfatase A; Arylsulfatase A; Cerebro Sulfatase Act; Chemistry; Fib; Fibr; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Metachromatic leucodystrophy; Narrative; Point in time; Random; Report; Saposin b |
2.21 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49322-1 |
Hemoglobin pattern |
Imp |
Bld |
Pt |
Nom |
HPLC |
|
ACTIVE |
Hemoglobin pattern [Interpretation] in Blood by HPLC |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
49322-1 |
|
HPLC |
|
|
Observation |
|
|
|
0 |
Hgb Fract Bld HPLC-Imp |
|
|
|
N |
|
Blood; Haemoglobin; Hb; HEMATOLOGY/CELL COUNTS; Hgb; Hgb Fract; High performance liquid chromatography; High pressure liquid chromatography; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Random; WB; Whole blood |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49323-9 |
Hemoglobin pattern |
Imp |
Bld |
Pt |
Nom |
Electrophoresis.citrate agar |
|
ACTIVE |
Hemoglobin pattern [Interpretation] in Blood by Electrophesis citrate agar |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
49323-9 |
|
Electrophoresis.citrate agar |
|
|
Observation |
|
|
|
0 |
Hgb Fract Bld Elph Citrate-Imp |
|
|
|
N |
|
Blood; Elec; Elect; Electr; Electro; Electrophhrs; Electrophrs; Elp; Elph; Elph Citrate; Ep; Haemoglobin; Hb; HEMATOLOGY/CELL COUNTS; Hgb; Hgb Fract; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Random; WB; Whole blood |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49324-7 |
11-Deoxycortisol^2H post dose metyraPONE |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
11-Deoxycortisol [Mass/volume] in Serum or Plasma --2 hours post dose metyraPONE |
|
MIN |
DefinitionDescription |
|
|
ug/dL |
|
|
|
|
|
|
CHAL |
|
49324-7 |
|
|
|
|
Observation |
|
|
|
0 |
11DC 2h p MTP SerPl-mCnc |
|
|
|
N |
|
11DC; 120 min; 120 minutes; 120min; 2 hours; 2h p MTP; After; CHEMISTRY.CHALLENGE TESTING; Compound S; Cortexolone; Cortodoxone; Deoxycortisol; Desoxycortisol; Level; Mass concentration; Metopirone; p dose; p metyraPONE; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.4 |
2.22 |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
| 49325-4 |
17-Hydroxypregnenolone^1H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --1 hour post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
49325-4 |
|
|
|
|
Observation |
|
|
|
0 |
17OH-Preg 1h p chal SerPl-mCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 17 alpha-Hydroxypregnanolone; 17 hydroxy pregnenolone; 17-alpha-Hydroxypregnenolone; 17alpha-Hydroxypregnenolone; 17OH-Preg; 1h p chal; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.22 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 49326-2 |
Aldosterone^2H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Aldosterone [Mass/volume] in Serum or Plasma --2 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
49326-2 |
|
|
|
|
Observation |
|
|
|
0 |
Aldost 2h p chal SerPl-mCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p chal; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
2.22 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 49327-0 |
Androstenedione^1H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Mass/volume] in Serum or Plasma --1 hour post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
49327-0 |
|
|
|
|
Observation |
|
|
|
0 |
Androst 1h p chal SerPl-mCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p chal; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; gamma-4-Androstenedione; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.22 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 49328-8 |
Clavulanate Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Clavulanate IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
49328-8 |
|
|
|
|
Both |
|
|
|
0 |
Clavulanate IgE Qn |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; c305; Clav; Clavate; Clavu; Clavul; Clavulanic; Clavulanic acid; Immune globulin E; Immunoglobulin E; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.7 |
2.22 |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
| 49329-6 |
Interferon.alpha Ab |
PrThr |
Ser/Plas |
Pt |
Ord |
IA |
|
ACTIVE |
Interferon alpha Ab [Presence] in Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
49329-6 |
|
IA |
|
|
Both |
|
|
|
0 |
IFN-A Ab SerPl Ql IA |
|
|
|
N |
|
ABS; Aby; Alfa; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; IFN; IFN-A; MEIA; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS |
2.56 |
2.22 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4933-8 |
HLA-DQ1 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-DQ1 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4933-8 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-DQ1 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; Removed lower case w from Component per HLA antigen nomenclature guidelines [http://hla.alleles.org/antigens/recognised_serology.html]; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49330-4 |
Renin^3H post XXX challenge |
CCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Renin [Enzymatic activity/volume] in Plasma --3 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL/h |
|
|
|
|
|
|
CHAL |
|
49330-4 |
|
|
|
|
Observation |
|
|
|
0 |
Renin 3h p chal Plas-cCnc |
|
|
|
N |
|
3h p chal; Active renin; After; Angiotensin forming enzyme; Angiotensinogenase; Cardio; Cardiology; Catalytic Concentration; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Heart Disease; Kidney; Nephrology; p chal; Pl; Plasma; Plasma renin activity; Plsm; Point in time; PRA; PST; QNT; Quan; Quant; Quantitative; Random; Renal |
2.42 |
2.22 |
|
|
|
|
|
|
|
ng/mL/h |
|
|
|
0 |
| 49331-2 |
Renin^2H post XXX challenge |
CCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Renin [Enzymatic activity/volume] in Plasma --2 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/mL/h |
|
|
|
|
|
|
CHAL |
|
49331-2 |
|
|
|
|
Observation |
|
|
|
0 |
Renin 2h p chal Plas-cCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p chal; Active renin; After; Angiotensin forming enzyme; Angiotensinogenase; Cardio; Cardiology; Catalytic Concentration; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Heart Disease; Kidney; Nephrology; p chal; Pl; Plasma; Plasma renin activity; Plsm; Point in time; PRA; PST; QNT; Quan; Quant; Quantitative; Random; Renal |
2.42 |
2.22 |
|
|
|
|
|
|
|
ng/mL/h |
|
|
|
0 |
| 49332-0 |
Vasopressin^30M post XXX challenge |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Vasopressin [Mass/volume] in Plasma --30 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
49332-0 |
|
|
|
|
Observation |
|
|
|
0 |
Vasopressin 30M p chal Plas-mCnc |
|
|
|
N |
|
30M p chal; ADH; Adiuretin; After; Antidiuretic hormone; Arginine vasopressin hormone; AVH; CHEMISTRY.CHALLENGE TESTING; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; VP |
2.42 |
2.22 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
| 49333-8 |
Galactitol |
SCnc |
Amnio fld |
Pt |
Qn |
|
|
ACTIVE |
Galactitol [Moles/volume] in Amniotic fluid |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
49333-8 |
|
|
|
|
Both |
|
|
|
0 |
Galactitol Amn-sCnc |
|
|
|
N |
|
AF; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; Chemistry; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.42 |
2.22 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 49334-6 |
Adenovirus DNA |
NCnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Adenovirus DNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
49334-6 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HAdV DNA # SerPl NAA+probe |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Adeno virus; Amplif; Amplification; Amplified; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HAdV; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.73 |
2.22 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 49335-3 |
Adenovirus DNA |
NCnc |
Tiss |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Adenovirus DNA [#/volume] (viral load) in Tissue by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
49335-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HAdV DNA # Tiss NAA+probe |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Adeno virus; Amplif; Amplification; Amplified; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HAdV; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Strand Displacement Amplification; Tissue; Tissue, unspecified; TMA; Transcription mediated amplification; Viral load |
2.7 |
2.22 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 49336-1 |
Adenovirus DNA |
NCnc |
BAL |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Adenovirus DNA [#/volume] (viral load) in Bronchoalveolar lavage by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
49336-1 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HAdV DNA # BAL NAA+probe |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Adeno virus; Amplif; Amplification; Amplified; Bronchial alveolar lavage; Bronchoalveolar lavage; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HAdV; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lung; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; Pulmonary; Pulmonology; QBR; QNT; Quan; Quant; Quantitative; Random; Respiratory; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.7 |
2.22 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 49337-9 |
Adenovirus DNA |
NCnc |
Bone mar |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Adenovirus DNA [#/volume] (viral load) in Bone marrow by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
49337-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HAdV DNA # Mar NAA+probe |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Adeno virus; Amplif; Amplification; Amplified; BM; BON; Bone marrow; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HAdV; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; MAR; Marrow (bone); Microbiology; minimal angle of resolution; Minimum angle of resolution; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.73 |
2.22 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 49338-7 |
Adenovirus DNA |
NCnc |
CSF |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Adenovirus DNA [#/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
49338-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HAdV DNA # CSF NAA+probe |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Adeno virus; Amplif; Amplification; Amplified; Cerebral spinal fluid; Cerebrospinal Fl; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HAdV; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Neuro; Neurology; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.7 |
2.22 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 49339-5 |
Adenovirus DNA |
NCnc |
Stool |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Adenovirus DNA [#/volume] (viral load) in Stool by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
49339-5 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HAdV DNA # Stl NAA+probe |
|
|
|
N |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; Adeno virus; Amplif; Amplification; Amplified; Bowel movement; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Faecal; Faeces; Fecal; Feces; Gastro; Gastroenterology; GI; HAdV; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Stl; Stool = Fecal; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.73 |
2.22 |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
0 |
| 4934-6 |
HLA-DQ2 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-DQ2 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4934-6 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-DQ2 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
